Published in Cancer Res on July 24, 2007
An NF-κB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest (2012) 2.13
Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules. Cell (2016) 2.03
Update on pancreatic intraepithelial neoplasia. Int J Clin Exp Pathol (2008) 1.87
Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal (2014) 1.61
Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-κB and MMPs. J Cell Biol (2013) 1.54
A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res (Phila) (2013) 1.53
Chemoprevention strategies for pancreatic cancer. Nat Rev Gastroenterol Hepatol (2010) 1.38
The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model. Cancer Prev Res (Phila) (2010) 1.28
Progressive metaplastic and dysplastic changes in mouse pancreas induced by cyclooxygenase-2 overexpression. Neoplasia (2008) 1.24
Synthetic triterpenoids prolong survival in a transgenic mouse model of pancreatic cancer. Cancer Prev Res (Phila) (2010) 1.19
Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48Cre/+ LSL-KrasG12D/+ mice. Int J Cancer (2012) 1.15
Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery (2008) 1.11
Cell intrinsic role of COX-2 in pancreatic cancer development. Mol Cancer Ther (2012) 1.10
High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) (2013) 1.08
RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. J Gastrointest Surg (2011) 1.00
Cyclooxygenase-deficient pancreatic cancer cells use exogenous sources of prostaglandins. Mol Cancer Res (2010) 0.97
Inhibition of pancreatic intraepithelial neoplasia progression to carcinoma by nitric oxide-releasing aspirin in p48(Cre/+)-LSL-Kras(G12D/+) mice. Neoplasia (2012) 0.97
Diclofenac inhibits tumor growth in a murine model of pancreatic cancer by modulation of VEGF levels and arginase activity. PLoS One (2010) 0.94
Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer (2013) 0.94
Pancreatic cancer and its stroma: a conspiracy theory. World J Gastroenterol (2014) 0.94
Prolonged survival and delayed progression of pancreatic intraepithelial neoplasia in LSL-KrasG12D/+;Pdx-1-Cre mice by vitamin E δ-tocotrienol. Carcinogenesis (2013) 0.91
Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas (2013) 0.91
Targeting pancreatitis blocks tumor-initiating stem cells and pancreatic cancer progression. Oncotarget (2015) 0.90
Involvement of COX-2/PGE(2) Pathway in the Upregulation of MMP-9 Expression in Pancreatic Cancer. Gastroenterol Res Pract (2011) 0.89
Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev Res (Phila) (2010) 0.89
CXCR2-Dependent Endothelial Progenitor Cell Mobilization in Pancreatic Cancer Growth. Transl Oncol (2011) 0.85
Experimental animal models of pancreatic carcinogenesis for prevention studies and their relevance to human disease. Cancers (Basel) (2011) 0.84
Pathogenesis of pancreatic cancer: lessons from animal models. Toxicol Pathol (2013) 0.84
Impact of diabetes type II and chronic inflammation on pancreatic cancer. BMC Cancer (2015) 0.84
Targeted therapies for pancreatic cancer. Br Med Bull (2008) 0.84
Cyclooxygenase-2 confers growth advantage to syngeneic pancreatic cancer cells. Pancreas (2011) 0.83
Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis. Cancer Metastasis Rev (2013) 0.82
Involvement of eicosanoids in the pathogenesis of pancreatic cancer: the roles of cyclooxygenase-2 and 5-lipoxygenase. World J Gastroenterol (2014) 0.82
The HMGA1-COX-2 axis: a key molecular pathway and potential target in pancreatic adenocarcinoma. Pancreatology (2012) 0.82
The Role of PPAR-gamma and Its Interaction with COX-2 in Pancreatic Cancer. PPAR Res (2008) 0.82
Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer. World J Gastroenterol (2016) 0.81
Molecular Targeted Intervention for Pancreatic Cancer. Cancers (Basel) (2015) 0.80
Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents. Semin Immunopathol (2012) 0.80
Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer. BMC Cancer (2013) 0.80
Chemoprevention of pancreatic cancer-one step closer. Langenbecks Arch Surg (2012) 0.80
E-cadherin expression in obesity-associated, Kras-initiated pancreatic ductal adenocarcinoma in mice. Surgery (2015) 0.79
Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production. Inflammation (2012) 0.79
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma. Oncotarget (2015) 0.78
Prostaglandin E2 activates the mTORC1 pathway through an EP4/cAMP/PKA- and EP1/Ca2+-mediated mechanism in the human pancreatic carcinoma cell line PANC-1. Am J Physiol Cell Physiol (2015) 0.78
Urinary prostaglandin E2 metabolite and pancreatic cancer risk: case-control study in urban Shanghai. PLoS One (2015) 0.77
Loss of Activin Receptor Type 1B Accelerates Development of Intraductal Papillary Mucinous Neoplasms in Mice With Activated KRAS. Gastroenterology (2015) 0.77
Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer. Pancreas (2016) 0.76
K-Ras and cyclooxygenase-2 coactivation augments intraductal papillary mucinous neoplasm and Notch1 mimicking human pancreas lesions. Sci Rep (2016) 0.75
Diabetes, Pancreatogenic Diabetes, and Pancreatic Cancer. Diabetes (2017) 0.75
Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism. Surgery (2017) 0.75
Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice. PLoS One (2017) 0.75
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res (2009) 2.36
Tuberculosis in seals caused by a novel member of the Mycobacterium tuberculosis complex: Mycobacterium pinnipedii sp. nov. Int J Syst Evol Microbiol (2003) 2.34
Pancreatic-pleural fistula is best managed by early operative intervention. Surgery (2009) 2.03
Evaluation of the guidelines for management of pancreatic branch-duct intraductal papillary mucinous neoplasm. Clin Gastroenterol Hepatol (2008) 1.82
Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol (2010) 1.82
Improved survival following pancreaticoduodenectomy to treat adenocarcinoma of the pancreas: the influence of operative blood loss. Arch Surg (2008) 1.73
Colonic stent vs. emergency surgery for management of acute left-sided malignant colonic obstruction: a decision analysis. Gastrointest Endosc (2004) 1.70
The Osler Fellowship: an apprenticeship for medical educators. Acad Med (2010) 1.59
Laparoscopic surgery for cancer: a systematic review and a way forward. J Am Coll Surg (2010) 1.58
Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats. Clin Chem (2006) 1.58
Controversies in clinical pancreatology: management of acute idiopathic recurrent pancreatitis. Pancreas (2003) 1.56
Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol (2009) 1.53
Predictors of stroke in patients paced for sick sinus syndrome. J Am Coll Cardiol (2004) 1.52
Hepatic oval cells have the side population phenotype defined by expression of ATP-binding cassette transporter ABCG2/BCRP1. Am J Pathol (2003) 1.49
Pancreatic serous cystadenocarcinoma: a case report and review of the literature. J Gastrointest Surg (2009) 1.47
Management of pancreatic fistulas after pancreaticoduodenectomy: results in 437 consecutive patients. Arch Surg (2005) 1.47
Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett (2006) 1.41
Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas (2003) 1.40
Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer (2003) 1.39
Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer (2002) 1.39
Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res (2005) 1.38
Role of pancreatic cancer-derived exosomes in salivary biomarker development. J Biol Chem (2013) 1.37
Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg (2006) 1.36
Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One (2009) 1.35
Natural history of intraductal papillary mucinous neoplasms (IPMN): current evidence and implications for management. J Gastrointest Surg (2007) 1.34
Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery (2011) 1.32
Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol (2008) 1.32
Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg (2003) 1.30
Accuracy of staging node-negative pancreas cancer: a potential quality measure. Arch Surg (2007) 1.25
Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas (2005) 1.25
Assessment of left ventricular function by different speckle-tracking software. Eur J Echocardiogr (2010) 1.23
Epidemiology, risk factors, and the promotion of pancreatic cancer: role of the stellate cell. J Gastroenterol Hepatol (2012) 1.23
PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun (2003) 1.22
Distal pancreatectomy: incidence of postoperative diabetes. J Gastrointest Surg (2008) 1.21
The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation. Gastroenterology (2011) 1.19
Baicalein, a component of Scutellaria baicalensis, induces apoptosis by Mcl-1 down-regulation in human pancreatic cancer cells. Biochim Biophys Acta (2011) 1.17
Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor. Cancer Res (2005) 1.17
Loss of acinar cell IKKα triggers spontaneous pancreatitis in mice. J Clin Invest (2013) 1.17
The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res (2005) 1.14
Expression analysis of the prostaglandin E2 production pathway in human pancreatic cancers. Pancreas (2008) 1.12
A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas (2005) 1.12
Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol (2011) 1.11
The Notch signaling pathway is related to neurovascular progression of pancreatic cancer. Ann Surg (2005) 1.11
Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery (2008) 1.11
The clinical significance of MAGEA3 expression in pancreatic cancer. Int J Cancer (2006) 1.11
High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model. Cancer Prev Res (Phila) (2013) 1.08
Tumor hypoxia correlates with metastatic tumor growth of pancreatic cancer in an orthotopic murine model. J Surg Res (2004) 1.07
VEGF-RII influences the prognosis of pancreatic cancer. Ann Surg (2002) 1.07
Opposing effects of n-6 and n-3 polyunsaturated fatty acids on pancreatic cancer growth. Pancreas (2008) 1.06
Echocardiographic assessment of pulmonary hypertension: standard operating procedure. Eur Respir Rev (2012) 1.06
Nerve growth factor stimulates MMP-2 expression and activity and increases invasion by human pancreatic cancer cells. Clin Exp Metastasis (2004) 1.05
Transcriptional regulation of urokinase-type plasminogen activator receptor by hypoxia-inducible factor 1 is crucial for invasion of pancreatic and liver cancer. Neoplasia (2009) 1.05
Metformin inhibits the growth of human pancreatic cancer xenografts. Pancreas (2013) 1.05
Human cytokine levels in nonperforated versus perforated appendicitis: molecular serum markers for extent of disease? Am Surg (2002) 1.05
VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery (2005) 1.04
The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas (2003) 1.02
An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas (2003) 1.01
Rottlerin stimulates apoptosis in pancreatic cancer cells through interactions with proteins of the Bcl-2 family. Am J Physiol Gastrointest Liver Physiol (2009) 1.00
Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinoma: a stage-matched comparison of outcomes. Cancer (2010) 1.00